George Washington University Hematology Update Symposium 2026

George Washington University Hematology Update Symposium 2026

$25.00
Skip to product information
George Washington University Hematology Update Symposium 2026
  • George Washington University Hematology Update Symposium 2026
  • George Washington University Hematology Update Symposium 2026
George Washington University Hematology Update Symposium 2026

George Washington University Hematology Update Symposium 2026

$25.00

George Washington University Hematology Update Symposium 2026

George Washington University Hematology Update Symposium 2026 | Myeloproliferative Neoplasms, CMML, Multiple Myeloma, Coagulation Disorders, AML, CLL, Lymphoma & Bone Marrow Failure

The George Washington University Hematology Update Symposium 2026 provides a comprehensive, evidence-based educational update on the latest diagnostic and therapeutic advances in malignant and nonmalignant hematology. Organized by the GW Cancer Center at The George Washington University School of Medicine and Health Sciences, this one-day educational symposium brings together nationally recognized experts in hematology, medical oncology, coagulation disorders, bone marrow diseases, and hematologic malignancies. Held on February 28, 2026, at the Hyatt Regency Bethesda in Maryland, the program reviews major developments in myeloproliferative neoplasms, chronic myelomonocytic leukemia, multiple myeloma, coagulation disorders, acute myeloid leukemia, chronic lymphocytic leukemia, lymphoma, and bone marrow failure syndromes. Directed by Robert S. Siegel, MD, the symposium emphasizes translating contemporary clinical evidence, emerging treatments, and evolving hematology practice standards into practical patient management. The GW Hematology Update 2026 curriculum combines disease-specific reviews, expert perspectives, and clinically relevant discussions to help healthcare professionals evaluate complex blood disorders and incorporate recent advances into everyday clinical practice.

Course Details

  • Course: George Washington University Hematology Update Symposium 2026
  • Official Event: 2026 Hematology Update Symposium
  • Organizer: The George Washington University School of Medicine and Health Sciences
  • Presented By: GW Cancer Center
  • Course Director: Robert S. Siegel, MD
  • Date: Saturday, February 28, 2026
  • Location: Bethesda, Maryland, USA
  • Venue: Hyatt Regency Bethesda
  • Venue Address: One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814
  • Official Event Format: Live, In-Person Symposium
  • Primary Specialty: Hematology
  • Additional Focus: Medical Oncology, Hematopathology, Internal Medicine, Coagulation Disorders and Bone Marrow Diseases
  • Language: English
  • Official AMA CME: Up to 7.00 AMA PRA Category 1 Credits™
  • ABIM MOC: Up to 7.00 MOC Points
  • Scientific Lectures: 7
  • Additional Program Sessions: Welcome and Introduction; Closing Remarks
  • Official Participant Resources: Electronic Syllabus, PDF Slide Handouts and Archived Session Recordings
The original GW educational activity provides eligible registered participants with access to educational materials and archived presentations through December 31, 2026, under the organizer's access policies. These publisher-hosted resources and professional credits are separate from any files distributed through MedicalAmboss.

Target Audience

The symposium is intended for healthcare professionals involved in the diagnosis, treatment, and multidisciplinary management of hematologic conditions. The target audience includes:
  • Hematologists
  • Medical Oncologists
  • Hematopathologists
  • Internal Medicine Physicians
  • Hematology-Oncology Specialists
  • Clinical Hematologists
  • Hospitalists
  • Oncology Nurses
  • Hematology Nurses
  • Physician Assistants
  • Nurse Practitioners
  • Advanced Practice Providers
  • Medical Residents
  • Hematology and Oncology Fellows
  • Allied Healthcare Professionals
  • Other Clinicians Involved in the Care of Patients With Blood Disorders
The program is especially relevant to clinicians seeking updates in hematologic malignancies, coagulation abnormalities, plasma cell disorders, and bone marrow failure syndromes.

Program Overview

Hematology continues to evolve rapidly as advances in molecular diagnostics, disease classification, targeted therapies, immunotherapy, and supportive care reshape the management of blood disorders. The George Washington University Hematology Update Symposium 2026 addresses these developments through a focused educational review of important hematologic conditions. The program covers:
  • Myeloproliferative Neoplasms
  • Chronic Myelomonocytic Leukemia
  • Multiple Myeloma
  • Plasma Cell Disorders
  • Coagulation Disorders
  • Acute Myeloid Leukemia
  • Chronic Lymphocytic Leukemia
  • Lymphoma
  • Bone Marrow Failure
  • Hematologic Disease Classification
  • Diagnostic Evaluation
  • Molecular and Cytogenetic Testing
  • Risk Stratification
  • Current Treatment Strategies
  • Emerging Targeted Therapies
  • Immunotherapeutic Approaches
  • Supportive Hematologic Care
  • Evidence-Based Clinical Decision-Making
The educational program integrates clinical research with practical diagnostic and management considerations relevant to hematology and oncology practice.

Learning Objectives

Upon successful participation in the original educational activity, participants should be better able to:
  1. Discuss recent diagnostic and therapeutic advances in hematology, including developments affecting hematologic malignancies and nonmalignant blood disorders.
  2. Evaluate contemporary scientific evidence involving malignant hematologic diseases, coagulation abnormalities, and bone marrow disorders.
  3. Apply current clinical evidence, practice recommendations, and diagnostic tools to improve patient assessment and individualized treatment planning.
  4. Formulate evidence-based approaches to complex hematologic conditions, including leukemia, lymphoma, plasma cell malignancies, and bone marrow failure syndromes.
  5. Review developments in the diagnosis, classification, risk assessment, and management of myeloproliferative neoplasms and chronic myelomonocytic leukemia.
  6. Evaluate evolving treatment strategies for multiple myeloma and related plasma cell disorders.
  7. Recognize common and complex coagulation abnormalities and consider appropriate diagnostic and therapeutic approaches.
  8. Review clinically important advances in acute myeloid leukemia and chronic lymphocytic leukemia.
  9. Examine contemporary diagnostic and treatment considerations for lymphoma.
  10. Identify major categories of bone marrow failure and understand principles of clinical evaluation and treatment selection.
The objectives above combine the stated course goals with educational themes reflected in the official program.

Official Program Topics

Saturday, February 28, 2026

All times are Eastern Time (ET).

Welcome and Introduction

Welcome | Introduction to Program

8:00 AM – 8:15 AM Faculty: Robert S. Siegel, MD Professor of Medicine; Associate Center Director for Education and Training, The George Washington University, GW Cancer Center The opening session introduces the symposium's educational focus on recent developments in hematology and the clinical application of new diagnostic and therapeutic evidence.

Session I – Myeloid Neoplasms

Myeloproliferative Neoplasms + CMML

8:15 AM – 9:15 AM Faculty: Ayalew Tefferi, MD Barbara Woodward Lips Professor of Medicine, Mayo Clinic This presentation reviews clinically important developments involving myeloproliferative neoplasms and chronic myelomonocytic leukemia. Myeloproliferative neoplasms represent a group of clonal hematopoietic disorders characterized by abnormal production of one or more blood cell lineages. Chronic myelomonocytic leukemia is a myeloid neoplasm with overlapping myelodysplastic and myeloproliferative features. Important clinical considerations include:
  • Myeloproliferative Neoplasms
  • Polycythemia Vera
  • Essential Thrombocythemia
  • Primary Myelofibrosis
  • Chronic Myelomonocytic Leukemia
  • Clonal Hematopoiesis
  • Molecular Mutations
  • JAK2, CALR and MPL Mutations
  • Diagnostic Classification
  • Bone Marrow Assessment
  • Disease Risk Stratification
  • Thrombotic Complications
  • Disease Progression
  • Current Treatment Approaches
  • Emerging Therapeutic Strategies
The session addresses disease-specific evaluation and the role of evolving scientific evidence in the management of myeloid neoplasms.

Session II – Plasma Cell Disorders

Multiple Myeloma

9:15 AM – 10:15 AM Faculty: Kenneth Anderson, MD Kraft Family Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School This session examines multiple myeloma, an important plasma cell malignancy associated with bone marrow infiltration, monoclonal protein production, and systemic complications. The educational discussion relates to evolving diagnostic and treatment strategies for plasma cell disorders. Important topics include:
  • Multiple Myeloma
  • Plasma Cell Dyscrasias
  • Monoclonal Gammopathies
  • Myeloma Diagnostic Criteria
  • Bone Marrow Evaluation
  • Molecular and Cytogenetic Risk Assessment
  • Monoclonal Protein Testing
  • Myeloma-Related Bone Disease
  • Renal Complications
  • Anemia
  • Hypercalcemia
  • Treatment Selection
  • Proteasome Inhibitors
  • Immunomodulatory Agents
  • Monoclonal Antibody Therapy
  • Cellular Immunotherapy
  • Bispecific Antibodies
  • Relapsed and Refractory Myeloma
  • Supportive Care
The topic highlights the importance of integrating disease biology, patient characteristics, and modern treatment approaches into clinical care.

Session III – Coagulation and Hemostasis

Disorders of Coagulation

10:30 AM – 11:15 AM Faculty: Kenneth A. Bauer, MD Professor of Medicine, Harvard Medical School; Beth Israel Deaconess Medical Center This session reviews clinically important disorders of coagulation and hemostasis. Coagulation abnormalities may result in excessive bleeding, thrombosis, or complex abnormalities involving several components of the hemostatic system. Important considerations include:
  • Coagulation Disorders
  • Hemostasis
  • Bleeding Disorders
  • Thrombotic Disorders
  • Inherited Coagulation Abnormalities
  • Acquired Coagulation Disorders
  • Coagulation Factor Deficiencies
  • Clinical Evaluation of Bleeding
  • Clinical Evaluation of Thrombosis
  • Laboratory Testing
  • Prothrombin Time
  • Activated Partial Thromboplastin Time
  • Mixing Studies
  • Anticoagulant Treatment Considerations
  • Diagnostic Algorithms
  • Management Principles
The presentation is relevant to clinicians involved in the assessment and treatment of patients with bleeding or thrombotic conditions.

Session IV – Acute Leukemia

Acute Myeloid Leukemia

11:15 AM – 12:00 PM Faculty: Samah Nassereddine, MD Assistant Professor of Medicine, The George Washington University, GW Cancer Center This presentation focuses on acute myeloid leukemia, a heterogeneous hematologic malignancy characterized by abnormal proliferation of myeloid precursor cells. Advances in molecular profiling and treatment approaches have increased the importance of accurate disease classification and risk-based management. Important educational considerations include:
  • Acute Myeloid Leukemia
  • Clinical Presentation
  • Bone Marrow Evaluation
  • AML Classification
  • Cytogenetic Abnormalities
  • Molecular Mutations
  • Risk Stratification
  • Diagnostic Testing
  • Induction Therapy
  • Consolidation Therapy
  • Targeted Treatment
  • Treatment of Older Adults
  • Relapsed and Refractory AML
  • Hematopoietic Stem Cell Transplantation
  • Treatment-Related Complications
  • Supportive Care
The session supports understanding of current clinical approaches to AML diagnosis and management.

Session V – Chronic Leukemia

Chronic Lymphocytic Leukemia

12:00 PM – 12:45 PM Faculty: Imad A. Tabbara, MD, FACP Chief, Division of Hematology/Oncology, DeCesaris Cancer Institute, Anne Arundel Medical Center; Clinical Professor of Medicine, The George Washington University This session reviews contemporary developments in chronic lymphocytic leukemia. CLL is a mature B-cell malignancy with considerable variation in clinical presentation, disease progression, and treatment requirements. Important clinical considerations include:
  • Chronic Lymphocytic Leukemia
  • B-Cell Malignancies
  • Clinical Presentation
  • Lymphocytosis
  • Diagnostic Flow Cytometry
  • Disease Staging
  • Prognostic Biomarkers
  • Molecular Risk Assessment
  • Observation and Active Surveillance
  • Indications for Treatment
  • Targeted Therapy
  • BTK Inhibitors
  • BCL-2 Inhibitors
  • Monoclonal Antibody Treatment
  • Relapsed and Refractory CLL
  • Treatment-Related Toxicities
  • Individualized Treatment Planning
The presentation explores the evolving management of CLL and the role of risk-adapted therapy.

Session VI – Lymphoid Malignancies

Lymphoma

1:45 PM – 2:45 PM Faculty: Nina Delaney Wagner-Johnston, MD Director of Lymphoma Drug Development, Sidney Kimmel Comprehensive Cancer Center; Professor of Oncology, Johns Hopkins University School of Medicine This session examines contemporary clinical approaches to lymphoma. Lymphomas represent a diverse group of lymphoid malignancies requiring accurate pathological classification, staging, prognostic assessment, and disease-specific treatment. Important discussion areas include:
  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • B-Cell Lymphomas
  • T-Cell Lymphomas
  • Lymphoma Classification
  • Clinical Presentation
  • Diagnostic Biopsy
  • Histopathology
  • Immunophenotyping
  • Molecular Testing
  • Disease Staging
  • Risk Stratification
  • Treatment Selection
  • Immunotherapy
  • Targeted Therapies
  • Cellular Therapy
  • Relapsed and Refractory Lymphoma
  • Treatment Toxicities
  • Long-Term Follow-Up
The presentation addresses the importance of integrating disease subtype, patient characteristics, and evolving therapeutic options.

Session VII – Bone Marrow Disorders

Bone Marrow Failure

2:45 PM – 3:45 PM Faculty: Mrinal S. Patnaik, MD Professor of Internal Medicine, Division of Hematology, Mayo Clinic This presentation reviews bone marrow failure and its diagnostic and therapeutic challenges. Bone marrow failure syndromes may result in reduced production of red blood cells, white blood cells, platelets, or multiple blood cell lineages. Important considerations include:
  • Bone Marrow Failure Syndromes
  • Aplastic Anemia
  • Myelodysplastic Neoplasms
  • Cytopenias
  • Pancytopenia
  • Bone Marrow Hypocellularity
  • Inherited Bone Marrow Failure
  • Acquired Bone Marrow Failure
  • Diagnostic Evaluation
  • Bone Marrow Biopsy
  • Cytogenetic Testing
  • Molecular Testing
  • Differential Diagnosis
  • Supportive Care
  • Immunosuppressive Treatment
  • Hematopoietic Stem Cell Transplantation
  • Treatment Selection
  • Long-Term Monitoring
The session emphasizes a systematic approach to identifying causes of bone marrow dysfunction and developing appropriate management plans.

Closing Session

Closing Remarks | Adjournment

3:45 PM – 4:00 PM Faculty: Robert S. Siegel, MD The concluding session summarizes important developments in hematology and closes the educational program.

Major Topics Covered

  • George Washington University Hematology Update Symposium 2026
  • Hematology Update
  • Medical Oncology
  • Hematologic Malignancies
  • Nonmalignant Hematology
  • Myeloproliferative Neoplasms
  • Polycythemia Vera
  • Essential Thrombocythemia
  • Primary Myelofibrosis
  • Chronic Myelomonocytic Leukemia
  • Molecular Hematology
  • JAK2 Mutations
  • CALR Mutations
  • MPL Mutations
  • Multiple Myeloma
  • Plasma Cell Disorders
  • Monoclonal Gammopathies
  • Myeloma Risk Stratification
  • Coagulation Disorders
  • Bleeding Disorders
  • Thrombotic Disorders
  • Hemostasis
  • Coagulation Testing
  • Acute Myeloid Leukemia
  • AML Classification
  • Molecular Profiling
  • Targeted Leukemia Therapy
  • Chronic Lymphocytic Leukemia
  • CLL Prognostic Markers
  • BTK Inhibitors
  • BCL-2 Inhibitors
  • Lymphoma
  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • B-Cell Lymphoma
  • T-Cell Lymphoma
  • Lymphoma Immunotherapy
  • CAR T-Cell Therapy
  • Bone Marrow Failure
  • Aplastic Anemia
  • Myelodysplastic Neoplasms
  • Cytopenias
  • Pancytopenia
  • Bone Marrow Biopsy
  • Hematopoietic Stem Cell Transplantation
  • Evidence-Based Hematology
  • Clinical Hematology Guidelines
  • Risk-Adapted Treatment
  • Supportive Hematologic Care

Myeloproliferative Neoplasms and CMML

Myeloproliferative neoplasms and chronic myelomonocytic leukemia represent important categories of clonal myeloid disease. Accurate evaluation may require integration of clinical findings, blood counts, bone marrow morphology, molecular abnormalities, and risk assessment. The symposium includes a focused session addressing developments in these disorders. Important clinical themes include:
  • Myeloid Disease Classification
  • Molecular Diagnostics
  • Risk Stratification
  • Thrombotic Complications
  • Disease Progression
  • Treatment Selection
  • Long-Term Monitoring
These topics are especially relevant to hematologists managing patients with chronic myeloid neoplasms.

Multiple Myeloma and Plasma Cell Disorders

Multiple myeloma management has evolved substantially with the development of targeted agents, monoclonal antibodies, and cellular immunotherapies. The curriculum provides an expert-led update on this important hematologic malignancy. Relevant topics include:
  • Plasma Cell Disease Diagnosis
  • Molecular Risk Assessment
  • Myeloma-Related Organ Damage
  • Modern Treatment Approaches
  • Immunomodulatory Therapies
  • Proteasome Inhibitors
  • Monoclonal Antibodies
  • Emerging Immunotherapies
  • Relapsed and Refractory Disease
  • Treatment-Related Toxicity
The educational focus supports an integrated understanding of diagnosis, treatment planning, and supportive care.

Coagulation and Hemostatic Disorders

Coagulation disorders may cause clinically significant bleeding, thrombosis, or abnormalities detected during laboratory investigation. The symposium addresses this broad field through an expert presentation on coagulation disorders. Important clinical considerations include:
  • Bleeding Assessment
  • Thrombotic Risk
  • Hemostatic Testing
  • Inherited Disorders
  • Acquired Disorders
  • Laboratory Interpretation
  • Differential Diagnosis
  • Anticoagulation
  • Evidence-Based Management
The topic is relevant to hematologists, internists, hospitalists, and other clinicians evaluating patients with suspected hemostatic abnormalities.

Acute Myeloid Leukemia

Acute myeloid leukemia is a biologically diverse malignancy that requires timely diagnosis and individualized management. Important aspects of clinical care include molecular classification, prognostic assessment, treatment selection, and management of complications. The symposium includes an update dedicated to AML, providing a framework for reviewing recent diagnostic and therapeutic developments.

Chronic Lymphocytic Leukemia

CLL treatment has undergone major changes with the introduction of targeted therapeutic strategies. Management decisions may depend on symptoms, disease burden, prognostic abnormalities, comorbidities, patient preferences, and treatment-associated risks. The course includes a dedicated CLL presentation emphasizing the evolving clinical management of this common mature B-cell malignancy.

Lymphoma Diagnosis and Management

Lymphoma includes multiple malignant lymphoid diseases with distinct clinical characteristics, biological behavior, and treatment approaches. Accurate diagnosis and management require coordination among hematologists, medical oncologists, hematopathologists, and other specialists. The symposium provides a focused review of lymphoma and developments in treatment. The educational emphasis includes disease classification, risk assessment, modern therapies, and management of challenging cases.

Bone Marrow Failure Syndromes

Bone marrow failure may cause anemia, neutropenia, thrombocytopenia, or pancytopenia. Its causes include acquired, inherited, immune-mediated, and clonal disorders. The course addresses clinical and diagnostic considerations relevant to bone marrow failure. Important principles include:
  • Evaluation of Cytopenias
  • Bone Marrow Morphology
  • Differential Diagnosis
  • Genetic and Molecular Testing
  • Supportive Treatment
  • Disease-Specific Therapy
  • Transplant Considerations
The session supports a structured understanding of complex bone marrow disorders.

Molecular Diagnostics and Precision Hematology

Molecular and cytogenetic testing increasingly contributes to disease classification, prognosis, and therapeutic decision-making in hematology. Relevant clinical applications include:
  • Identification of Driver Mutations
  • Disease Classification
  • Prognostic Risk Assessment
  • Treatment Selection
  • Monitoring Disease Evolution
  • Recognition of Therapeutic Targets
The symposium's disease-focused sessions provide context for evaluating these developments across multiple hematologic disorders.

Evidence-Based Clinical Decision-Making

Modern hematology requires integration of clinical findings, laboratory results, pathological examination, molecular information, and emerging therapeutic evidence. Important clinical responsibilities include:
  • Establishing Accurate Diagnoses
  • Evaluating Disease Severity
  • Performing Risk Stratification
  • Selecting Appropriate Treatment
  • Monitoring Treatment Response
  • Recognizing Complications
  • Coordinating Multidisciplinary Care
  • Applying Current Clinical Evidence
The GW Hematology Update 2026 program is designed to support the translation of scientific developments into practical clinical management.

Course Leadership

Robert S. Siegel, MD

  • Professor of Medicine
  • Associate Center Director for Education and Training
  • The George Washington University, GW Cancer Center
Dr. Siegel serves as the official Course Director of the 2026 Hematology Update Symposium.

Official Faculty

The published 2026 program includes the following faculty:
  • Robert S. Siegel, MD — The George Washington University
  • Ayalew Tefferi, MD — Mayo Clinic
  • Kenneth Anderson, MD — Dana-Farber Cancer Institute / Harvard Medical School
  • Kenneth A. Bauer, MD — Harvard Medical School / Beth Israel Deaconess Medical Center
  • Samah Nassereddine, MD — The George Washington University
  • Imad A. Tabbara, MD, FACP — The George Washington University / Anne Arundel Medical Center
  • Nina Delaney Wagner-Johnston, MD — Johns Hopkins University
  • Mrinal S. Patnaik, MD — Mayo Clinic
These faculty members bring expertise in myeloid neoplasms, plasma cell disorders, coagulation, leukemia, lymphoma, and bone marrow disease.

Continuing Medical Education

The George Washington University School of Medicine and Health Sciences designated the original live activity for a maximum of:
  • 7.00 AMA PRA Category 1 Credits™
  • 7.00 ABIM Maintenance of Certification Points
The George Washington University School of Medicine and Health Sciences is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Eligible participants must satisfy the provider's attendance, completion, and evaluation requirements to claim applicable credits.

Important CME Notice

The credit amounts above apply only to eligible participation in the original George Washington University educational activity. Purchasing separately distributed educational materials from MedicalAmboss does not provide:
  • GW CME Credits
  • ABIM MOC Points
  • Official Completion Certificates
  • University Conference Registration
  • Live Symposium Attendance
  • GW Educational Platform Access
  • Publisher Accounts
  • Official Online Recording Access
  • Other Publisher-Hosted Benefits

Why This Course Is Relevant

The George Washington University Hematology Update Symposium 2026 addresses important developments in the diagnosis and treatment of blood disorders. Hematology clinicians frequently evaluate patients with:
  • Myeloproliferative Neoplasms
  • Chronic Myelomonocytic Leukemia
  • Multiple Myeloma
  • Coagulation Abnormalities
  • Acute Myeloid Leukemia
  • Chronic Lymphocytic Leukemia
  • Lymphoma
  • Bone Marrow Failure
  • Unexplained Cytopenias
These conditions require accurate assessment, interpretation of clinical and laboratory evidence, appropriate risk stratification, and individualized treatment strategies. The symposium combines disease-specific updates with perspectives from experienced hematology specialists. Its focused curriculum makes it particularly relevant for hematologists, medical oncologists, hematopathologists, internal medicine physicians, and other healthcare professionals involved in the care of patients with hematologic diseases.

Official Program Reference and MedicalAmboss Purchase Scope

Official George Washington University Symposium: https://cme.smhs.gwu.edu/hematology-and-oncology-best-practices-courses/content/2026-hematology-update-symposium Official 2026 Course Agenda: https://cme.smhs.gwu.edu/sites/default/files/media/2025-11/2026%20Hematology%20Update%20Symposium%20Course%20Syllabus.pdf The official references describe the original conference, including the scheduled sessions, faculty, accreditation, venue, and participation arrangements. They do not establish the exact inventory of digital files available through a separately distributed MedicalAmboss listing. MedicalAmboss File Scope: This listing describes the educational subject matter for reference. Provider registration, live attendance, streaming-platform access, CME or other credit, certificates, memberships, apps, accounts, and publisher-hosted extras are not included unless explicitly listed as store files.

Short Description

<div style="border:2px solid #1677b8;border-radius:10px;padding:16px;background:#f7fbfe;"> George Washington University Hematology Update Symposium 2026 provides a comprehensive, evidence-based update on malignant and nonmalignant hematology, featuring leading experts from GW Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, Harvard Medical School, and Johns Hopkins University. The February 28, 2026 symposium covers myeloproliferative neoplasms, chronic myelomonocytic leukemia, multiple myeloma, coagulation disorders, acute myeloid leukemia, chronic lymphocytic leukemia, lymphoma, and bone marrow failure.

Topics

  • Welcome- Siegel RS
  • Myeloproliferative Neoplasms
  • Multiple Myeloma
  • Disorders of Coagulation
  • Acute Myeloid Leukemia
  • Chronic Lymphocytic Leukemia
  • Lymphoma
  • Bone Marrow Failure
  • Closing Adjournment

You may also like